Please login to the form below

Not currently logged in
Email:
Password:

filibuvir

This page shows the latest filibuvir news and features for those working in and with pharma, biotech and healthcare.

AbbVie gets 'breakthrough' status for hepatitis C regimen

AbbVie gets 'breakthrough' status for hepatitis C regimen

In March Pfizer dropped HCV candidate filibuvir after a strategic review of its pipeline, while last year BMS abandoned its polymerase inhibitor BMS-986094 candidate after a patient death in trials.

Latest news

  • Pfizer drops hepatitis C candidate filibuvir Pfizer drops hepatitis C candidate filibuvir

    Pfizer drops hepatitis C candidate filibuvir. Compound was lagging behind investigational drugs from Gilead and AbbVie. ... The decision to drop filibuvir, reported by the Wall Street Journal on Friday, effectively means that Pfizer has withdrawn from

  • HCV hope on the horizon

    Tibotec). Among the polymerase inhibitors, the most advanced in development is Pfizer's non-nucleoside compound filibuvir at phase II.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics